2023-09-09T22:49:16+03:00[Europe/Moscow] en true <p>irreversible inhibitor of <strong><span class="tt-bg-yellow">COX-1 enzyme</span></strong>; reduces <strong><span class="tt-bg-yellow">formation and release of TXA2</span></strong></p>, <p>TXA2</p>, <p>7-10 days; platelets can't make new proteins</p>, <p>-grel suffix</p>, <p>a, b</p>, <p>-antagonize <strong><span class="tt-bg-yellow">ADP-receptor P2Y12</span><sub><span class="tt-bg-yellow">; </span></sub><span class="tt-bg-yellow">reduce platelet aggregation</span></strong></p>, <p>a</p>, <p>a</p>, <p>a</p>, <p>a, b</p>, <p>d</p>, <p>c</p>, <p>d</p>, <p>c</p>, <p>c</p>, <p>c</p>, <p>c</p>, <p>c</p>, <p>-antagonize <strong><span class="tt-bg-yellow">glycoprotein IIb/IIIa</span></strong> receptors for <strong><span class="tt-bg-yellow">fibrinogen, vitronectin</span></strong>, and <strong><span class="tt-bg-yellow">vWF</span></strong></p>, <p>abciximab, eptifibatide, tirofiban </p>, <p>b</p>, <p>a</p>, <p>b</p>, <p>c</p>, <p>b,c</p>, <p>Cilostazol </p>, <p>induces <strong><span class="tt-bg-yellow">vasodilation</span></strong> coupled with an <strong><span class="tt-bg-yellow">antiplatelet </span></strong>effect by decreasing</p><p>synthesis of <strong><span class="tt-bg-yellow">TXA2</span></strong> &amp; other <strong><span class="tt-bg-yellow">platelet aggregating factors</span></strong></p>, <p>treatment of PAD</p>, <p>f; treats pain-associated w/ walking </p> flashcards
Pharmacology (Anti-platelet drugs)

Pharmacology (Anti-platelet drugs)

Customize
collection saved
Share
Long Term Learning Spaced Repetition
Add to Long Term Learning Desk
Fast learning Repeat this set of flashcards
Preview Test Spell
Play
Match
Review

  • irreversible inhibitor of COX-1 enzyme; reduces formation and release of TXA2

    Aspirin MOA?

  • TXA2

    -stimulates activation of new platelets and increases platelet aggregation

  • 7-10 days; platelets can't make new proteins

    How long does the activity of aspirin on platelet COX-1 last?

    Why?

  • -grel suffix

    How can we identify ADP pathway inhibitors?

  • a, b

    Which are prodrugs?

    a) clopidogrel

    b) prasugrel

    c) Ticagrelor

    d) Cangrelor

  • -antagonize ADP-receptor P2Y12; reduce platelet aggregation

    ADP pathway inhibitors moa?

  • a

    Which has the slowest onset of action?

    a) clopidogrel

    b) prasugrel

    c) Ticagrelor

    d) Cangrelor

  • a

    Which has the lowest platelet inhibition?

    a) clopidogrel

    b) prasugrel

    c) Ticagrelor

    d) Cangrelor

  • a

    Which is metabolized by CYP2C19 ?

    a) clopidogrel

    b) prasugrel

    c) Ticagrelor

    d) Cangrelor

  • a, b

    Which are irreversible inhibitors of P2Y12?

    a) clopidogrel

    b) prasugrel

    c) Ticagrelor

    d) Cangrelor

  • d

    Which is administered via IV?

    a) clopidogrel

    b) prasugrel

    c) Ticagrelor

    d) Cangrelor

  • c

    Which has the highest risk of intracranial bleeding?

    a) clopidogrel

    b) prasugrel

    c) Ticagrelor

    d) Cangrelor

  • d

    Which has DDI w/ Prasugrel or Clopidogrel?

    a) clopidogrel

    b) prasugrel

    c) Ticagrelor

    d) Cangrelor

  • c

    Which can cause dyspnea?

    a) clopidogrel

    b) prasugrel

    c) Ticagrelor

    d) Cangrelor

  • c

    Which is orally active?

    a) clopidogrel

    b) prasugrel

    c) Ticagrelor

    d) Cangrelor

  • c

    Which do we avoid inhibitors of CYP3A in?

    a) clopidogrel

    b) prasugrel

    c) Ticagrelor

    d) Cangrelor

  • c

    Which can increase serum concentrations of simvastatin & lovastatin?

    a) clopidogrel

    b) prasugrel

    c) Ticagrelor

    d) Cangrelor

  • c

    Which can interfere with Digoxin metabolism?

    a) clopidogrel

    b) prasugrel

    c) Ticagrelor

    d) Cangrelor

  • -antagonize glycoprotein IIb/IIIa receptors for fibrinogen, vitronectin, and vWF

    glycoprotein IIb/IIIa inhibitor MOA?

  • abciximab, eptifibatide, tirofiban

    What are the Glycoprotein IIb/IIIa inhibitors (3)

  • b

    How are Glycoprotein IIb/IIIa inhibitors administered?

    a) orally

    b) IV

    c) patch

    d) SQ

  • a

    Which is a chimeric monoclonal Ab?

    a) Abciximab

    b) Eptifibatide

    c) Tirofiban

  • b

    Which is a peptide analog?

    a) Abciximab

    b) Eptifibatide

    c) Tirofiban

  • c

    Which is a peptidomimetic analog?

    a) Abciximab

    b) Eptifibatide

    c) Tirofiban

  • b,c

    Which are competitive antagonists?

    a) Abciximab

    b) Eptifibatide

    c) Tirofiban

  • Cilostazol

    What is our PDE3 inhibitor?

  • induces vasodilation coupled with an antiplatelet effect by decreasing

    synthesis of TXA2 & other platelet aggregating factors

    PDE3 inhibitor MOA

  • treatment of PAD

    What are PDE3 inhibitors used for?

  • f; treats pain-associated w/ walking

    PDE3 inhibitors are proven to reduce the risk of CV death. T/F?